Recombinant Human TROY/TNFRSF19 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human TROY/TNFRSF19 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Lgr5/GPR49 Fc Chimera (Catalog # 8078-GP) is coated at 0.5 μg/mL, Recombinant Human TROY/TNFRSF19 Fc Chimera binds with an apparent K_d <500 nM.
• Source: Mouse myeloma cell line, NS0-derived human TROY/TNFRSF19 protein
  

  Human TROY (Glu30-Leu170) Accession # AAF71828	DIEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: AAF71828
• N-terminal Sequence: Glu30
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: TNFRSF19
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 42 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 50-55 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human TROY/TNFRSF19 Fc Chimera Protein, CF

• TAJ
• TAJ-alpha
• TAJToxicity and JNK inducer
• TNFRSF19
• TRADE
• TROY
• TROYtumor necrosis factor receptor superfamily member 19
• tumor necrosis factor receptor superfamily, member 19

Background

TROY (also known as TAJ and TNFRSF19) is a 45‑55 kDa member of the TNF receptor superfamily of molecules (1‑4). It is widely expressed in the embryo, but shows limited expression in adult. In particular, embryonic TROY is found in embryonic epithelium, neural tube, and mesenchyme, and developing neurons of the hippocampus and thalamus (5, 6). In the adult, TROY is found in the nervous system associated with dorsal root and retinal ganglia neurons, astrocytes, and microglia, and in hair follicles where it is expressed by dermal papilla matrix cells (4, 7, 8, 9). In human, TROY has also been found on melanoma cells, not normal melanocytes (10). TROY is reportedly a component of the Nogo-A receptor, taking the place of p75 in a membrane-bound LINGO-1:NgR1:TROY complex (6, 8, 9). This complex purportedly mediates axon repulsion initiated by one of five myelin-associated inhibitory factors (OMpg; CD100; Ephrin B3; Nogo-A; MAG) (6, 11). In the hair follicle, TROY binds LTa and acts with Eda to drive secondary hair follicle development (4, 12). Mature human TROY is a 394 amino acid (aa) type I transmembrane protein (1‑3). It possesses a 141 aa extracellular region (aa 30‑170) that contains three 40 aa TNFR cysteine motifs, and an extended 232 aa cytoplasmic domain (aa 192‑423). There is one potential isoform that shows a two aa substitution for aa 416‑423. The extracellular domains of human and mouse TROY share 90% aa identity.

1. Hu, S. et al. (1999) Genomics 62:103.
2. Eby, M.T. et al. (2000) J. Biol. Chem. 275:15336.
3. Kojima, T. et al. (2000) J. Biol. Chem. 275:20742.
4. Hashimoto, T. et al. (2008) Cell Cycle 7:106.
5. Pispa, J. et al. (2003) Gene Exp. Patterns 3:675.
6. Mi, S. (2008) Cytokine Growth Factor Rev. 19:245.
7. Satoh, J. et al. (2007) Neuropathol. Appl. Neurobiol. 33:99.
8. Shao, Z. et al. (2005) Neuron 45:353.
9. Park, J.B. et al. (2000) Neuron 45:345.
10. Spanjaard, R.A. et al. (2007) Int. J. Cancer 120:1304.
11. Venkatesh, K. et al. (2007) J. Cell Biol. 177:393.
12. Pispa, J. et al. (2008) Hum. Mol. Genet. 17:3380.

Publications for TROY/TNFRSF19 (1548-TR)(1)

Publication using 1548-TR

• Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-07-26;487(7408):505-9. 2012-07-26 [PMID: 22763448] (Bioassay, Human)

Bioinformatics

• Gene Symbol: TNFRSF19
• Uniprot:
  • AAF71828()